Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Up – Should You Buy?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) gapped up prior to trading on Tuesday . The stock had previously closed at $20.69, but opened at $21.95. Hikma Pharmaceuticals shares last traded at $21.95, with a volume of 200 shares.

Analyst Ratings Changes

Separately, Barclays lowered Hikma Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 6th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Hikma Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.72 and a current ratio of 1.24. The firm’s 50-day simple moving average is $20.99 and its 200 day simple moving average is $22.07.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.